The Stakes Are High

Corcept Therapeutics (CORT) has a lot riding on December 30, 2025. That's the PDUFA target date for Relacorilant, a drug candidate that could either transform the company into a multi-product operation or leave it dependent on a single revenue stream for another three to five years. If the FDA delivers bad news, Corcept's valuation will likely take a hit, since there's nothing else in the pipeline close to approval.

The real question investors should be asking: are there red flags in the clinical data that might trigger a complete response letter?

When One Trial Says Yes and Another Says Maybe

Relacorilant is a selective glucocorticoid receptor antagonist designed to manage hypercortisolism symptoms in patients with endogenous Cushing's syndrome. The New Drug Application relies on two Phase 3 trials, and here's where things get interesting.

The GRACE trial enrolled patients with endogenous Cushing's syndrome across all causes. It hit its primary endpoint, showing that patients who switched to placebo faced significantly higher risk of losing blood pressure control. Good news.

The GRADIENT trial, however, focused specifically on patients with adrenal-origin Cushing's syndrome and failed to meet its primary endpoint of reducing mean systolic blood pressure. This suggests Relacorilant might work better in non-adrenal patients, who represent the majority of Cushing's syndrome cases.

But here's the problem: the NDA seeks approval for all endogenous Cushing's syndrome patients, including those with adrenal adenomas. That GRADIENT miss could give the FDA pause and increase the risk of a complete response letter. The silver lining? Relacorilant's safety profile looks solid.

The Financial Picture Looks Stable

With a market capitalization of $8.9 billion, Corcept sits in a comfortable financial position. The company carries no long-term debt and maintains strong liquidity. R&D and SG&A expenses have climbed recently, but that's entirely expected as the company ramps up clinical work and prepares for potential commercialization ahead of the PDUFA date.

Share count has remained essentially flat, with no signs that Corcept needs to raise capital through dilutive equity financing. Revenue growth from Korlym, their first approved drug, continues funding pipeline development. Bottom line: the balance sheet is solid, even if the regulatory pathway has some bumps.